adjusted life year
Where’s WALY? : A proof of concept study of the ‘wellbeing adjusted life year’ using secondary analysis of cross sectional survey data
10
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
8
Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia
9
Disability-Adjusted Life-Year Burden of Abusive Head Trauma at Ages 0–4
8
The work environment disability-adjusted life year for use with life cycle assessment: a methodological approach
16
Headroom beyond the quality adjusted life year
11
Willingness to pay for one quality-adjusted life year in Iran
10
The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013
18
A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal
8
Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base
8
Older patients with traumatic brain injury present with a higher GCS score than younger patients for a given severity of injury
18
The global burden of injury: Incidence, mortality, disability-adjusted life years and time trends from the global burden of disease study 2013
18
Clinical effectiveness and cost effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
16
An economic evaluation of an augmented cognitive behavioural intervention vs. computerized cognitive training for post-stroke depressive symptoms
12
Update: Eliciting societal preferences for weighting QALY's according to burden of illness, size of gain and end of life
38
Delivering reproductive health services through non-state providers in Pakistan: understanding the value for money of different approaches
10
METFORMIN THE TIME TESTED TRUSTWORTHY MEDICINE IN THE MANAGEMENT OF TYPE 2 DIABETES
18
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case
7
Maternal and reproductive health financing in Burundi: public sector contribution levels and trends from 2010 to 2012
11
Burden of disease resulting from lead exposure at toxic waste sites in Argentina, Mexico and Uruguay
9